Reported Earnings • May 14
First quarter 2026 earnings released First quarter 2026 results: Revenue: CA$648.1k (down 44% from 1Q 2025). Net loss: CA$399.6k (down CA$464.8k from profit in 1Q 2025). Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Announcement • Apr 07
Innovotech Inc., Annual General Meeting, Jun 16, 2026 Innovotech Inc., Annual General Meeting, Jun 16, 2026. Location: alberta, edmonton Canada Reported Earnings • Apr 04
Full year 2025 earnings released Full year 2025 results: Revenue: CA$4.53m (up 107% from FY 2024). Net income: CA$94.4k (down 58% from FY 2024). Profit margin: 2.1% (down from 10% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 81% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. New Risk • Mar 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 9.8% per year over the past 5 years. High level of non-cash earnings (68% accrual ratio). Market cap is less than US$10m (CA$8.32m market cap, or US$6.06m). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Revenue is less than US$5m (CA$4.5m revenue, or US$3.2m). Announcement • Feb 07
Innovotech Inc. Announces Executive Changes, Effective February 1, 2026 Innovotech Inc. announced the appointments of Jodi McDonald as Chief Operating Officer and Rod Szarka as Chief Commercial Officer (CCO) of the Company, each effective February 1, 2026. Ms. McDonald was previously President of Keystone Labs Inc. (Keystone), which was recently amalgamated with Innovotech Labs Corporation (Labs). Both Keystone and Labs were wholly owned subsidiaries of Innovotech Inc., and their amalgamation into a single entity as Innovotech Labs Corporation was previously announced on January 2, 2026, having been completed on January 1st, 2026. Ms. McDonald has led Keystone for more than 20 years, building and scaling a regulated laboratory business with a strong focus on quality, client service and team development. She holds a Bachelor of Science in Medical Laboratory Science from the University of Alberta. The company announced the appointment of Rod Szarka as Chief Commercial Officer. Mr. Szarka was previously Vice President of Marketing and Business Development at Keystone, where he was responsible for building client relationships and expanding service offerings. In his new role as CCO of Innovotech, Mr. Szarka will oversee revenue generation across the Company, including responsibility for business development, client relationships and the buildout of a dedicated sales and client service team for all Innovotech business lines.out of a dedicated sales and client service team for all Innovotech business lines. Rod has a strong track record of translating technical capabilities into clear value for clients, added Dr. Milne. His experience growing Keystones client base and his understanding of the needs of regulated life sciences companies make him the right leader to build out Innovotechs commercial engine. With Jodi focused on operations and Rod focused on growth, we are strengthening the leadership team needed to scale our life sciences business. New Risk • Dec 04
New major risk - Revenue and earnings growth Earnings have declined by 9.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 9.8% per year over the past 5 years. High level of non-cash earnings (68% accrual ratio). Market cap is less than US$10m (CA$10.5m market cap, or US$7.54m). Minor Risk Revenue is less than US$5m (CA$4.5m revenue, or US$3.2m). Announcement • Nov 21
Innovotech Inc. announced that it has received CAD 0.2 million in funding On November 20, 2025, Innovotech Inc. closed the transaction. No finders' fees were paid with respect to the offering. The company announced that it has closed on the convertible debenture for an aggregate principal amount of CAD 200,000. The debenture and all accrued and unpaid interest shall mature on October 15, 2030, being 60 months from the date of issuance of the debenture. The principal amount of the debenture may, at the option of the debenture holder, be converted, in whole or in part, at any time before the maturity date into common shares of company at a price of CAD 0.25 per common share. Recent Insider Transactions Derivative • Sep 28
Independent Director exercised options to buy CA$118k worth of stock. On the 24th of September, Shong-Tak Tam exercised options to buy 589k shares at a strike price of around CA$0.17, costing a total of CA$100k. This transaction amounted to 22% of their direct individual holding at the time of the trade. Since December 2024, Shong-Tak's direct individual holding has increased from 1.85m shares to 2.72m. Company insiders have collectively bought CA$430k more than they sold, via options and on-market transactions, in the last 12 months. Reported Earnings • Aug 21
Second quarter 2025 earnings released: CA$0.005 loss per share (vs CA$0.003 loss in 2Q 2024) Second quarter 2025 results: CA$0.005 loss per share (further deteriorated from CA$0.003 loss in 2Q 2024). Revenue: CA$984.3k (up 147% from 2Q 2024). Net loss: CA$239.5k (loss widened 109% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Recent Insider Transactions • May 19
Independent Director recently bought CA$92k worth of stock On the 14th of May, Shong-Tak Tam bought around 434k shares on-market at roughly CA$0.21 per share. This transaction amounted to 21% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought CA$279k more in shares than they have sold in the last 12 months. Reported Earnings • May 15
First quarter 2025 earnings released First quarter 2025 results: Revenue: CA$1.16m (up 269% from 1Q 2024). Net income: CA$65.2k (up CA$167.4k from 1Q 2024). Profit margin: 5.6% (up from net loss in 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Announcement • May 06
Innovotech Inc., Annual General Meeting, Jul 08, 2025 Innovotech Inc., Annual General Meeting, Jul 08, 2025. Reported Earnings • Apr 16
Full year 2024 earnings released Full year 2024 results: Revenue: CA$2.19m (up 86% from FY 2023). Net income: CA$224.7k (up CA$382.3k from FY 2023). Profit margin: 10% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 103 percentage points per year, which is a significant difference in performance. Reported Earnings • Nov 20
Third quarter 2024 earnings released Third quarter 2024 results: Revenue: CA$436.1k (up 150% from 3Q 2023). Net loss: CA$21.3k (loss narrowed 82% from 3Q 2023). New Risk • Nov 14
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 32% per year over the past 5 years. Revenue is less than US$1m (CA$1.2m revenue, or US$878k). Market cap is less than US$10m (CA$6.13m market cap, or US$4.38m). Minor Risk Shareholders have been diluted in the past year (5.0% increase in shares outstanding). Reported Earnings • Aug 22
Second quarter 2024 earnings released Second quarter 2024 results: Revenue: CA$398.6k (down 3.0% from 2Q 2023). Net loss: CA$114.8k (down 258% from profit in 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 115 percentage points per year, which is a significant difference in performance. Recent Insider Transactions Derivative • Aug 18
President exercised options to buy CA$5.6k worth of stock. On the 15th of August, Craig Milne exercised options to buy 40k shares at a strike price of around CA$3,200, costing a total of CA$128m. This transaction amounted to 14% of their direct individual holding at the time of the trade. Since September 2023, Craig's direct individual holding has increased from 160.00k shares to 294.00k. Company insiders have collectively bought CA$128m more than they sold, via options and on-market transactions, in the last 12 months. Announcement • May 16
Innovotech Inc., Annual General Meeting, Jul 16, 2024 Innovotech Inc., Annual General Meeting, Jul 16, 2024. Reported Earnings • Apr 25
Full year 2023 earnings released: CA$0.004 loss per share (vs CA$0.004 loss in FY 2022) Full year 2023 results: CA$0.004 loss per share (in line with FY 2022). Revenue: CA$1.18m (up 5.0% from FY 2022). Net loss: CA$157.6k (loss widened 15% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance. Announcement • Dec 13
Innovotech Inc. Announces CFO Changes Innovotech Inc. has appointed Bernard Grobbelaar as CFO, effective immediately. Mr. Grobbelaar's new role is part of a greater realignment at Innovotech to strengthen the company's operations and improve its efficiency and capacity to scale. Mr. Grobbelaar will relinquish his Board of Directors seat, allowing him to maintain maximum independence. Mr. Grobbelaar is a Chartered Professional Accountant and provides services through his professional services firm, Oikonomos. The appointment of Mr. Grobbelaar completes a planned transition with Alan Savage concurrently resigning from his role as Innovotech CFO which the Board of Directors has accepted. Reported Earnings • Dec 01
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: CA$174.8k (down 49% from 3Q 2022). Net loss: CA$117.5k (down 382% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings. Board Change • Sep 15
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 4 experienced directors. 2 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Karen Farkas was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Announcement • Aug 27
Innovotech Inc. (TSXV:IOT) acquired 60% stake in Nou Life Sciences Inc.. Innovotech Inc. (TSXV:IOT) entered into an agreement to acquire 60% stake in Nou Life Sciences Inc. on August 18, 2020. The transaction is in return for completing an investment of CAD 0.1 million in development expenses in Nou Life’s patented skin treatment technology. The transaction allows Innovotech to take up to two years to evaluate the technology, which rests on the linking of alpha lipoic acid and L-carnitine. David Tam is a common director of both the Company and Nou Life. As of January 19, 2021, TSX Venture Exchange approved the transaction.Innovotech Inc. (TSXV:IOT) completed the acquisition of 60% stake in Nou Life Sciences Inc. on August 25, 2023. Reported Earnings • Aug 16
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: CA$411.0k (up 58% from 2Q 2022). Net income: CA$72.9k (up CA$135.4k from 2Q 2022). Profit margin: 18% (up from net loss in 2Q 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 29% per year whereas the company’s share price has fallen by 31% per year. Announcement • Aug 08
Innovotech Inc., Annual General Meeting, Oct 10, 2023 Innovotech Inc., Annual General Meeting, Oct 10, 2023. Board Change • Jul 14
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Independent Director Karen Farkas was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 28
Full year 2022 earnings released: CA$0.004 loss per share (vs CA$0.009 profit in FY 2021) Full year 2022 results: CA$0.004 loss per share (down from CA$0.009 profit in FY 2021). Revenue: CA$1.13m (down 24% from FY 2021). Net loss: CA$136.5k (down 137% from profit in FY 2021). Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Board Change • Apr 21
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Independent Director Karen Farkas was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Jan 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Independent Director Karen Farkas was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 16
Third quarter 2022 earnings released Third quarter 2022 results: Revenue: CA$340.5k (up 44% from 3Q 2021). Net income: CA$41.7k (up CA$63.2k from 3Q 2021). Profit margin: 12% (up from net loss in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Announcement • Oct 28
Innovotech Inc. Announces Retirement of Gerard Tertzakian as Director Innovotech Inc. announced that Dr. Gerard Tertzakian has retired from the Board after 20 years as a Director. Gerry was a Founder, former President and CEO, of Innovotech. Reported Earnings • Aug 18
Second quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.004 profit in 2Q 2021) Second quarter 2022 results: CA$0.002 loss per share (down from CA$0.004 profit in 2Q 2021). Revenue: CA$259.6k (down 46% from 2Q 2021). Net loss: CA$62.5k (down 138% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has only increased by 30% per year, which means it is significantly lagging earnings growth. Announcement • Aug 06
Innovotech Inc., Annual General Meeting, Oct 11, 2022 Innovotech Inc., Annual General Meeting, Oct 11, 2022. Board Change • Aug 02
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent Director Karen Farkas was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • May 02
Full year 2021 earnings released: EPS: CA$0.009 (vs CA$0.003 in FY 2020) Full year 2021 results: EPS: CA$0.009 (up from CA$0.003 in FY 2020). Revenue: CA$1.48m (up 24% from FY 2020). Net income: CA$367.1k (up 245% from FY 2020). Profit margin: 25% (up from 8.9% in FY 2020). Over the last 3 years on average, earnings per share has increased by 112% per year but the company’s share price has only increased by 47% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 25
Second quarter 2021 earnings released The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: CA$480.2k (up 44% from 2Q 2020). Net income: CA$163.7k (up 34% from 2Q 2020). Profit margin: 34% (down from 37% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 34% per year, which means it is well ahead of earnings. Reported Earnings • May 27
First quarter 2021 earnings released The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CA$308.6k (up 144% from 1Q 2020). Net income: CA$22.2k (up CA$137.5k from 1Q 2020). Profit margin: 7.2% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 110 percentage points per year, which is a significant difference in performance. Reported Earnings • Apr 24
Full year 2020 earnings released: EPS CA$0.003 (vs CA$0.001 loss in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CA$1.19m (up 21% from FY 2019). Net income: CA$106.3k (up CA$155.1k from FY 2019). Profit margin: 8.9% (up from net loss in FY 2019). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 118 percentage points per year, which is a significant difference in performance. Is New 90 Day High Low • Jan 12
New 90-day high: CA$0.25 The company is up 14% from its price of CA$0.22 on 08 October 2020. The Canadian market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 13% over the same period. Reported Earnings • Nov 16
Third quarter 2020 earnings released: EPS CA$0.003 The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: CA$351.5k (up 41% from 3Q 2019). Net income: CA$93.2k (up CA$78.0k from 3Q 2019). Profit margin: 27% (up from 6.1% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 107% per year but the company’s share price has increased by 36% per year, which means it is well ahead of earnings.